Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S BARTLETT

Showing results (171-180 of 386) with videos related to

Pageof 39
Sort By:
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
British Journal of Cancer|September 19, 2002
Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancerA D Watters, Z Latif, A Forsyth, et al.
Histopathology|November 26, 2013
Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situMary Anne Quintayo, Jane Starczynski, Fu Jian Yan, et al.
The Journal of Pathology|August 10, 2005
AKT activation predicts outcome in breast cancer patients treated with tamoxifenTove Kirkegaard, Caroline J Witton, Liane M McGlynn, et al.
Breast Cancer Research : BCR|April 16, 2004
Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingSian M Tovey, Caroline J Witton, John M S Bartlett, et al.
British Journal of Cancer|January 13, 2006
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancerA M Al Murri, J M S Bartlett, P A Canney, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?M Aapro, C J H van de Velde, C Markopoulos, et al.
BMC Genomics|December 3, 2011
Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experimentsRobert R Kitchen, Vicky S Sabine, Arthur A Simen, et al.
The Biochemical Journal|June 1, 1996
An H(+)-ATPase regulates cytoplasmic pH in Pneumocystis carinii trophozoitesR Docampo, N M Vanderheyden, M M Shaw, et al.
British Journal of Cancer|February 15, 2007
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomasM Aubele, G Auer, A K Walch, et al.
Pageof 39

Showing results (171-180 of 386) with videos related to

Sort By:
Pageof 39
Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.
British Journal of Cancer|September 19, 2002
Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancerA D Watters, Z Latif, A Forsyth, et al.
Histopathology|November 26, 2013
Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situMary Anne Quintayo, Jane Starczynski, Fu Jian Yan, et al.
The Journal of Pathology|August 10, 2005
AKT activation predicts outcome in breast cancer patients treated with tamoxifenTove Kirkegaard, Caroline J Witton, Liane M McGlynn, et al.
Breast Cancer Research : BCR|April 16, 2004
Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingSian M Tovey, Caroline J Witton, John M S Bartlett, et al.
British Journal of Cancer|January 13, 2006
Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancerA M Al Murri, J M S Bartlett, P A Canney, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?M Aapro, C J H van de Velde, C Markopoulos, et al.
BMC Genomics|December 3, 2011
Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experimentsRobert R Kitchen, Vicky S Sabine, Arthur A Simen, et al.
The Biochemical Journal|June 1, 1996
An H(+)-ATPase regulates cytoplasmic pH in Pneumocystis carinii trophozoitesR Docampo, N M Vanderheyden, M M Shaw, et al.
British Journal of Cancer|February 15, 2007
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomasM Aubele, G Auer, A K Walch, et al.
Pageof 39